Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.